Batlle Montserrat, Roig Eulàlia, Perez-Villa Fèlix, Lario Sergio, Cejudo-Martin Pilar, García-Pras Ester, Ortiz José, Roqué Mercé, Orús Josefina, Rigol Montserrat, Heras Magdalena, Ramírez José, Jimenez Wladimiro
Experimental Cardiology Laboratory, Hospital Clínic de Barcelona and Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
J Heart Lung Transplant. 2006 Sep;25(9):1117-25. doi: 10.1016/j.healun.2006.04.012. Epub 2006 Aug 9.
The activation of the renin-angiotensin system (RAS) contributes to the progression of left ventricular dysfunction. A novel human homologue of the angiotensin-converting enzyme (ACE), named ACE2, has been described but its role in human heart failure (HF) has not been elucidated. Besides, there is controversy as to whether the major angiotensin II-forming-activity in heart is ACE or chymase released from mast cells. Furthermore, long-term blockade of nitric oxide (NO) synthesis has been shown to increase ACE activity. To assess the locally activated vasoactive mediators that may contribute to the ventricular deterioration process, we sought to simultaneously analyze their expression in failing hearts.
We analyzed left ventricular biopsies from 30 patients with heart failure undergoing heart transplantation and 12 organ donors. The mRNA levels of ACE, ACE2, chymase and endothelial nitric oxide synthase (eNOS), were quantified by real-time polymerase chain reaction and mast cell density was assessed by immunohistochemistry. The mRNA levels of the atrial natriuretic peptide (ANP) and the brain natriuretic peptide (BNP) were also quantified as controls.
There was higher ACE and chymase mRNA expression and mast cell density in failing than in control myocardium and no changes in ACE2 expression were detected. eNOS mRNA levels were lower in failing hearts. Both ANP and BNP expression were higher in pathological than in control samples.
These data document a decompensation of vasoactive systems that may contribute to the progressive impairment of the myocardial function in HF. On the other hand, ACE2 mRNA expression is not altered in human end-stage HF.
肾素-血管紧张素系统(RAS)的激活促进左心室功能障碍的进展。一种名为血管紧张素转换酶2(ACE2)的新型人类血管紧张素转换酶(ACE)同源物已被描述,但其在人类心力衰竭(HF)中的作用尚未阐明。此外,关于心脏中主要的血管紧张素II生成活性是由ACE还是肥大细胞释放的糜酶介导存在争议。此外,长期阻断一氧化氮(NO)合成已被证明会增加ACE活性。为了评估可能导致心室恶化过程的局部激活的血管活性介质,我们试图同时分析它们在衰竭心脏中的表达。
我们分析了30例接受心脏移植的心力衰竭患者和12例器官供体的左心室活检组织。通过实时聚合酶链反应定量ACE、ACE2、糜酶和内皮型一氧化氮合酶(eNOS)的mRNA水平,通过免疫组织化学评估肥大细胞密度。心房利钠肽(ANP)和脑利钠肽(BNP)的mRNA水平也作为对照进行定量。
与对照心肌相比,衰竭心肌中ACE和糜酶的mRNA表达及肥大细胞密度更高,未检测到ACE2表达的变化。衰竭心脏中eNOS的mRNA水平较低。病理样本中ANP和BNP的表达均高于对照样本。
这些数据证明了血管活性系统的失代偿,这可能导致HF中心肌功能的进行性损害。另一方面,在人类终末期HF中ACE2的mRNA表达未改变。